Magstim® is a British-based medical device manufacturer and leading supplier of Transcranial Magnetic Stimulation (TMS) equipment, coils and complete packages used for both Magstim TMS Therapy and neuromodulation research.

Magstim TMS Therapy for depression is an effective, non-invasive, outpatient treatment, with few known adverse effects.

Approved as a safe and effective treatment for depression by the UK National Institute of Health and Care Excellence (NICE), TMS therapy was initially cleared by the USA Food and Drug Administration (FDA) in 2008 as a treatment for adults with major depression who have failed to respond to at least one antidepressant.

Specifically, Magstim holds six 510(k) clearances for its TMS therapy systems including the 3-minute, 19-minute and 37.5-minute treatment sessions as well as the first FDA-cleared navigation system designed for the clinical setting.

The Magstim name is at the forefront of the evolution of TMS from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).

As the innovator and maker of the most widely-used TMS stimulators in the world, the Magstim brand is trusted by more researchers and clinicians than any other manufacturer.

85% of TMS research published worldwide uses Magstim stimulators and Magstim’s product range provides users with the versatility and capability needed for a wide range of research applications.

Magstim employs over 100 people, the majority of which work at our head offices in West Wales, UK and Minnesota, USA.

With representation in over 70 countries and systems in more than 90 countries worldwide, Magstim is proud to be The Brains Behind TMS™.